Sonire Therapeutics Awarded $13 Million Through NEDO Deep-Tech Startups Support Program (DTSU) to Advance Global Commercialization of Pancreatic Cancer Treatment
Non-dilutive funding will support the commercialization, development, and expansion strategy for Sonire’s Ultrasound-Guided HIFU Platform
PALO ALTO, Calif., June 17, 2026 /PRNewswire/ — Sonire Therapeutics, a U.S.-based clinical-stage medical device company pioneering non-invasive ultrasound therapies for cancer treatment, today announced that Sonire Therapeutics KK, the firm’s Japan-based group company, has been selected for the New Energy and Industrial Technology Development Organization’s (NEDO) Deep-Tech Startups Support Program, which is one of Japan’s largest government-backed initiatives focused on accelerating the commercialization of breakthrough technologies.
Through NEDO, Sonire has been awarded approximately $13 million in non-dilutive funding to support the advancement of its proprietary High-Intensity Focused Ultrasound (HIFU) therapy platform. The funding will support manufacturing scale-up, regulatory approval activities in Japan, expansion into additional clinical indications, and acceleration of the company’s ongoing U.S. clinical development efforts.
